A third shot of Sinopharm’s Covid-19 vaccine leads to a rebound in antibody levels that drop months after a second dose, a small-scale Chinese study showed.

Bharat Biotech’s intranasal Covid-19 vaccine candidate is expected to enter the Phase II portion of a Phase II/III study within the next few weeks. BBV154 marks the second vaccine against the novel coronavirus developed by the India-based company.

Vaccine developer Novavax Inc. said on Sept. 8 the company initiated an early-stage study to test a combination of the flu shot NanoFlu and the Covid-19 vaccine NVX-CoV2373.

The Bill & Melinda Gates Foundation will make a $35 million equity investment in privately owned Exscientia Ltd. to fund the development of antiviral drugs including for the coronavirus, the Oxford-based drug developer said on Sept. 8.

Pfizer Inc. started dosing in a mid-to-late-stage trial of the company’s oral antiviral therapy for Covid-19 in non-hospitalized, symptomatic adult patients.

A new study on Covid-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection. 

A new coronavirus variant that was first detected in South Africa during May does not appear to be spreading, the World Health Organization said on Aug. 31, adding WHO was monitoring the variant as the virus evolves.

The number of coronavirus patients in U.S. hospitals breached 100,000, the highest level in eight months, according to the Department of Health and Human Services, as a resurgence of Covid-19 spurred by the highly contagious Delta variant strains the nation’s health care system.

Pfizer Inc. on Aug. 25 said a booster dose of the company’s two-shot Covid-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the drugmaker seeks U.S. regulatory approval for a third injection.

A booster dose of Johnson & Johnson’s Covid-19 vaccine sharply increased levels of antibodies against the coronavirus, according to interim data from two small, early-stage trials, the company said in a press release on Aug. 25.